Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 16.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensato |
Stammdaten
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Unternehmen & Branche
| Name | Chemomab Therapeutics Ltd. |
|---|---|
| Ticker | CMMB |
| CIK | 0001534248 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | ADR |
| Marktkapitalisierung | 9,2 Mio. USD |
| Beta | 0,58 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2023-03-31 | 10-Q | -8,753,000 | 0.04 | 35,013,000 | 27,954,000 | |
| 2022-12-31 | 10-K | -27,646,000 | 0.12 | 43,063,000 | 36,223,000 | |
| 2022-09-30 | 10-Q | -8,080,000 | 0.04 | 50,219,000 | 44,624,000 | |
| 2022-06-30 | 10-Q | -6,190,000 | 0.03 | 56,378,000 | 51,836,000 | |
| 2022-03-31 | 10-Q | -5,104,000 | 0.02 | 60,956,000 | 57,236,000 | |
| 2021-12-31 | 10-K | -12,478,000 | 0.06 | 64,353,000 | 61,466,000 | |
| 2021-09-30 | 10-Q | -2,968,000 | 0.01 | 67,440,000 | 65,512,000 | |
| 2021-06-30 | 10-Q | -2,770,000 | 0.01 | 70,518,000 | 68,039,000 | |
| 2021-03-31 | 10-Q | -1,704,000 | 60,123,000 | 55,164,000 | ||
| 2020-12-31 | 10-K | -5,951,000 | 12,476,000 | 10,802,000 | ||
| 2020-09-30 | 10-Q | -1,224,000 | 7,689,000 | 12,157,000 | ||
| 2020-06-30 | 10-Q | -1,081,000 | 10,016,000 | 12,796,000 | ||
| 2020-03-31 | 10-Q | -1,695,000 | 15,183,000 | 10,724,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.